• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections

byConstance Wu
September 3, 2019
in StudyGraphics
Reading Time: 2 mins read
1
Share on FacebookShare on Twitter

1. No significant difference in severe UTIs was observed between patients starting SGLT-2 inhibitors for type 2 diabetes, compared to DPP-4 inhibitors or GLP-1 agonists.

Evidence Rating Level: 2 (Good)

Study Rundown: The sodium glucose cotransporter-2 (SGLT-2) inhibitors are a newer class of diabetic medications that act by inhibiting glucose reabsorption in the proximal tubule, thereby reducing serum glucose levels. Since SGLT-2 inhibitors increase the availability of glucose in the urinary tract, there is concern the mechanism might promote bacterial growth. Studies have suggested that SGLT-2 inhibitors increase the risk of mild and moderate urinary tract infections (UTIs); however, findings are currently conflicting. This study utilized two large databases of U.S. commercial claims. The primary aim was to assess whether the initiation of SLGT-2 inhibitor therapy was associated with increased risk for severe UTIs. Inclusion criterion consisted of patients with type 2 diabetes, ages 18 or older, and had initiated SGLT-2 use, versus DPP-4 inhibitors or GLP-1 agonists. The study found that SGLT-2 inhibitors were not associated with increased risk for severe UTI compared with other anti-diabetic medications.. One limitation of this study was that the patient cohort was restricted to those with commercial insurance; therefore, the study results may not be fully generalizable to other patient groups.

Click to read the study in Annals of Internal Medicine

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Type 2 diabetes and abnormal amyloid concentrations are associated with accelerated brain atrophy

#VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes

Artificial intelligence based clinical decision systems are safe and effective for diabetes management

Tags: diabetesDPP-4 inhibitorsGLP-1 agonistSGLT-2 inhibitorsurinary tract infection (UTI)
Previous Post

The PIONEER 6 trial: semaglutide in type 2 diabetic patients does not increase cardiovascular risk

Next Post

Quick Take: Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL)

RelatedReports

Chronic Disease

Type 2 diabetes and abnormal amyloid concentrations are associated with accelerated brain atrophy

July 7, 2025
#VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes
StudyGraphics

#VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes

July 7, 2025
Pediatric DKA associated with recent acute care visits
Chronic Disease

Artificial intelligence based clinical decision systems are safe and effective for diabetes management

July 3, 2025
Low free sugar diet reduces hepatic steatosis in nonalcoholic fatty liver disease in adolescent males
Chronic Disease

Sodium-glucose cotransporter 2 inhibitors may decrease risk of serious liver events in patients with cirrhosis

July 2, 2025
Next Post
Evidence-based interventions for pediatric asthma successfully adapted for community health centers

Quick Take: Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL)

The STORM trial: treatment refractory multiple myeloma patients experience response with selinexor

The STORM trial: treatment refractory multiple myeloma patients experience response with selinexor

#VisualAbstract: Immediate Transfusion in African Children with Uncomplicated Severe Anemia

#VisualAbstract: Immediate Transfusion in African Children with Uncomplicated Severe Anemia

Please login to join discussion

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Digital health apps may have limited role in reduction of migraine symptoms
  • Living in a marginalized neighbourhood is associated with worse outcomes in patients with myocardial infarction
  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.